Xi’an Salus Nutra Inc Established in 2015 and located in Hi-Tech industrial Zone in xi’an city, which is the most advanced area in northwest china . Salus Nutra is a professional company specialized in natural plant extracts, collagen and high technology chemical API field in scientific research, producing and marketing.

Our products are mainly used in healthcare supplement, chemicals ,pharmaceutical, cosmetics and food additives. We are also engaged in supplying customization OEM service to help customers choose their right ingredients and develop their broad markets .

Our factory is located in BaoJi ,shaanxi province, it coveries an area of XX acres and equips with 2 standard production workshops meet with State Health Standards ,meanwhile employs more than 500 people with well-educated, including undergraduate, Postgraduate and some technical persons with rich experience.

Salus is committed to supplying safe, pure and healthy products that meet the high expectations of our customers. Experienced and dedicated members of the Quality and food safety Department work to provide in-depth analyses, testing and monitoring of our products, during and after the manufacturing processes and ensure the quality and safety according to the highest standards.

We are based on the honest and mutual benefits, rely on the reliable quality and best after-sale service to make good reputations both online and offline. Now it shares a great popularities from the customers at overseas. Our primary goal aims to solve customer problems through research & development & technical service .

If you have any doubts or confusion, YES, Salus will present the exactly right answer.

Best Price Ibudilast

Ibudilast is a potential oral treatment for all forms of multiple sclerosis (MS) and for other neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS). The drug, currently in clinical testing for these diseases, has been marketed in Japan and Korea to treat post-stroke complications and bronchial asthma for over two decades.

Ibudilas use in relapsing-remitting multiple sclerosis (RRMS). In 2016, the drug received Fast Track designation from the U.S. Food and Drug Administration (FDA) to help speed its development as an MS treatment.